Answers are grounded in this paper and cite their sources.
BackgroundOral lichen planus (OLP) is a common T–cell mediated chronic inflammatory disease, with unknown etiology. One of the etiological factors is involvement of some systemic diseases such as liver disease, diabetes mellitus, and hypertension. The immune system disturbances and oxidative stress may play a role in its pathogenesis. Corticosteroids are the mainstay for treatment of OLP and have its side effects. Oleozone gel was another suggested medication used to treat OLP.AimThe aim was to evaluate the beneficial effect of oleozone gel in the treatment of atrophic/erosive lichen planus in medically compromised patients and to compare it with the effect of triamcinolone acetonide in ora-base as a gold standard treatment.Materials and methodsTwenty patients with symptomatic atrophic/erosive OLP were medically compromised and randomly assigned for treatment with 0.1% triamcinolone acetonide gel (group 1) or oleozone gel (group 2). The pain score (visual analog scale) and tumor necrosis factor-α were assessed at baseline (before treatment), 1 month and 3 months.ResultsShowed nonsignificant differences between the two treatment groups in reducing visual analog scale score and tumor necrosis factor-α value.ConclusionThe study revealed that oleozone gel was found to be effective as triamcinolone acetonide in ora-base (0.1%) gel in the treatment of atrophic/erosive OLP in medically compromised patients.
No takes yet. Share an insight, caveat, or question.
Meligy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: